MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.

Core Viewpoint - MediPharm Labs Corp. is urging shareholders to be cautious regarding the election of three Dissident Nominees associated with Apollo Technology Capital Corporation, citing concerns over their past involvement with Check-Cap Ltd. and its governance issues [1][2][18]. Summary of Recent Events at Check-Cap - Check-Cap has faced significant governance challenges, including poor transparency, high turnover, and questionable cash resource allocation, leading to a decline in shareholder value [3][6]. - A notable incident involved Check-Cap transferring millions of dollars to Apollo and its subsidiaries, which raises concerns about the motives of the Dissident Nominees [4][11]. - The Check-Cap Board approved a $6 million loan to Nobul and transferred $11 million to a segregated account for Nobul's growth initiatives, despite no formal business combination being completed [8][9]. Connections to the Dissident Nominees - Three of the six Dissident Nominees for MediPharm's Board have been directly involved in Check-Cap's governance issues, raising questions about their qualifications to lead another public company [11][14]. - The involvement of these individuals in Check-Cap's tumultuous history suggests a potential risk for MediPharm shareholders [12][18]. Shareholder Voting Assistance - MediPharm encourages shareholders to vote using the GREEN proxy in support of the Company's nominees, emphasizing the importance of disregarding communications from the Dissident Nominees [19][20]. Company Background - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis products and has a GMP license from Health Canada, positioning it as a leader in the cannabinoid sector [21][23]. - The Company expanded its reach through the acquisition of VIVO Cannabis Inc., enhancing its presence in the medical cannabis market [24].